Copy to clipboard 
Movmedix, formerly L.A.R.S. (Laboratoire d’Application et de Recherche Scientifique), is the developer of the Ligament Advanced Reinforcement System artificial ligament (LARS). The company posted global revenue of over €8.5 million (~USD $9.3 million) in 2021, +60% vs. 2020.
Movmedix designs, develops and manufactures artificial implants used in orthopedic and trauma surgery. These devices are intended to replace or reinforce a natural ligament injured at the knee or shoulder joint, and prevent a transplant from the tendon taken from the patient. The aim is to reduce the length of hospitalization and rehabilitation, the risk of morbidity and infection, as well as pain.
In 2021, the company doubled its workforce (24 employees in total) and generated 95% of its export sales, including more than 60% in China, its preferred market, for which a subsidiary was created the same year. The company holds a presence in more than 25 countries.
In 2022, Movmedix celebrates its 30th anniversary and aims to achieve revenue of €12 million, an increase of more than 40% compared to 2021. The company seeks to grow its employee base in France in the areas of regulatory and quality, clinical study, marketing, administrative and production.
As part of its development, Movmedix continues to innovate on two new generations of ligaments:
Fourth-generation Biomimetic Ligament: an artificial ligament with a coating intended to mask the body’s response to a foreign element. This is intended to control the inflammatory response and improve the mechanical strength of the prosthesis. A clinical study is underway, and this system may be marketed by 2024.
Fifth-generation Biomimetic and Bioresorbable Ligament: a ligament with a coating grafted onto a bioresorbable material to promote the growth of a new natural ligament.
“We are in a major development phase for our team. Our growth in international markets has dramatically accelerated, with over 70% of our revenue coming from Asia-Pacific markets, including Australia, Taiwan, Vietnam and China. In China, the creation of a local team was essential. We are now targeting the North and South American markets, as well as Japan,” said Hervé Legrand, Managing Director.
Source: Movmedix
Movmedix, formerly L.A.R.S. (Laboratoire d'Application et de Recherche Scientifique), is the developer of the Ligament Advanced Reinforcement System artificial ligament (LARS). The company posted global revenue of over €8.5 million (~USD $9.3 million) in 2021, +60% vs. 2020.
Movmedix designs, develops and manufactures artificial implants used in...
Movmedix, formerly L.A.R.S. (Laboratoire d’Application et de Recherche Scientifique), is the developer of the Ligament Advanced Reinforcement System artificial ligament (LARS). The company posted global revenue of over €8.5 million (~USD $9.3 million) in 2021, +60% vs. 2020.
Movmedix designs, develops and manufactures artificial implants used in orthopedic and trauma surgery. These devices are intended to replace or reinforce a natural ligament injured at the knee or shoulder joint, and prevent a transplant from the tendon taken from the patient. The aim is to reduce the length of hospitalization and rehabilitation, the risk of morbidity and infection, as well as pain.
In 2021, the company doubled its workforce (24 employees in total) and generated 95% of its export sales, including more than 60% in China, its preferred market, for which a subsidiary was created the same year. The company holds a presence in more than 25 countries.
In 2022, Movmedix celebrates its 30th anniversary and aims to achieve revenue of €12 million, an increase of more than 40% compared to 2021. The company seeks to grow its employee base in France in the areas of regulatory and quality, clinical study, marketing, administrative and production.
As part of its development, Movmedix continues to innovate on two new generations of ligaments:
Fourth-generation Biomimetic Ligament: an artificial ligament with a coating intended to mask the body’s response to a foreign element. This is intended to control the inflammatory response and improve the mechanical strength of the prosthesis. A clinical study is underway, and this system may be marketed by 2024.
Fifth-generation Biomimetic and Bioresorbable Ligament: a ligament with a coating grafted onto a bioresorbable material to promote the growth of a new natural ligament.
“We are in a major development phase for our team. Our growth in international markets has dramatically accelerated, with over 70% of our revenue coming from Asia-Pacific markets, including Australia, Taiwan, Vietnam and China. In China, the creation of a local team was essential. We are now targeting the North and South American markets, as well as Japan,” said Hervé Legrand, Managing Director.
Source: Movmedix
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
